

Department of Origin: Integrated Healthcare Services	Effective Date: 12/12/23
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 12/05/23
Clinical Policy Document: Cardiac Devices & Procedures for Occlusion of Left Atrial Appendage	Replaces Effective Clinical Policy Dated: 12/06/22
Reference #: MC/A008	Page: 1 of 6

PURPOSE:

The intent of this clinical policy is to ensure services are medically necessary

Please refer to the member’s benefit document for specific information. To the extent there is any inconsistency between this policy and the terms of the member’s benefit plan or certificate of coverage, the terms of the member’s benefit plan document will govern.

POLICY:

Benefits must be available for health care services. Health care services must be ordered by a provider. Health care services must be medically necessary, applicable conservative treatments must have been tried, and the most cost-effective alternative must be requested for coverage consideration.

GUIDELINES:

Medical Necessity Criteria – Requests for left atrial appendage closure (LAAC) - Must satisfy any of the following: I or II

- I. Requests for percutaneous endovascular closure (occlusion) of the left atrial appendage (LAA) to reduce the risk of stroke (eg, Watchman/Watchman FLX) – must satisfy all of the following: A – C
 - A. The member has a diagnosis of nonvalvular atrial fibrillation; and
 - B. The member is at moderate to high risk of embolic stroke (CHA₂DS₂-VASc score greater than or equal to 2); and
 - C. Documentation of contraindication to long-term anticoagulation, such as but not limited to any of the following: 1 – 3
 1. Has an elevated risk of bleeding on oral anticoagulant with a *HAS-BLED* score equal to or greater than 3; or
 2. Recurrent falls with injury; or
 3. Has other absolute contraindication(s) to long-term anticoagulation.

- II. Requests for surgical closure (occlusion) of the LAA as part of cardiac surgery with cardiopulmonary bypass for a different indication to reduce the risk of stroke (eg, Amplatzer devices [Cardiac Plug and Amulet]) – must satisfy all of the following: A – C
 - A. Member is greater than or equal to 18 years of age; and
 - B. Member has a history of atrial fibrillation; and
 - C. The member is at moderate to high risk of embolic stroke (CHA₂DS₂-VASc score greater than or equal to 2).

Department of Origin: Integrated Healthcare Services	Effective Date: 12/12/23
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 12/05/23
Clinical Policy Document: Cardiac Devices & Procedures for Occlusion of Left Atrial Appendage	Replaces Effective Clinical Policy Dated: 12/06/22
Reference #: MC/A008	Page: 2 of 6

NOT ROUTINELY COVERED:

Combination of transcatheter aortic valve implantation (TAVI) and left atrial appendage occlusion procedure

EXCLUSIONS (not limited to):

Refer to member's Certificate of Coverage or Summary Plan Description

The following is considered investigative (see Investigative List)

- Thoracoscopic closure (occlusion) of the left atrial appendage (LAA) as a stand-alone procedure or as an adjunct to thoracoscopic atrial fibrillation ablation

DEFINITIONS:

CHADS2:

Estimates stroke risk in patients with atrial fibrillation. Each letter in the name represents something that may increase the chances of having a stroke. For each one that applies, add 1 or 2 points:

C: Congestive heart failure. If you have this, it counts for 1 point.

H: High blood pressure. If present, add a point.

A: Age. Are you 75 years old or older? If so, add a point.

D: Diabetes. If present, add a point

S: Stroke. History of stroke or a transient ischemic attack (TIA), add 2 points.

Score will be between 0 and 6 points:

Zero: Low risk for a stroke.

One point: Medium risk of stroke.

Two or more points: Medium to high risk of stroke.

CHA2DS2-VASc:

Estimates stroke risk in patients with atrial fibrillation. Includes CHADS2 elements plus 3 additional measures.

V: Vascular disease. If present, add a point.

A: Age. Are you 65 to 74 years old? If so, add a point.

Sc: Sex category. If you're a woman, add 1 point.

The total of these plus the CHADS2 score can be up to 9 points. The results scale is the same as for CHADS2.

<https://www.webmd.com/heart-disease/atrial-fibrillation/chads-score-overview>

HAS-BLED Score:

Estimates bleeding risk based on the following

- Hypertension (1 point)
- Abnormal liver function (1 point)
- Abnormal renal function (1 point)
- Stroke (1 point)
- Bleeding tendency or predisposition (1 point)
- Labile INRs in patients taking warfarin (1 point)
- Elderly: age greater than 65 years (1 point)
- Drugs: concomitant antiplatelet agent(s) or NSAIDS (1 point)
- Drugs: alcohol abuse (1 point)

Department of Origin: Integrated Healthcare Services	Effective Date: 12/12/23
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 12/05/23
Clinical Policy Document: Cardiac Devices & Procedures for Occlusion of Left Atrial Appendage	Replaces Effective Clinical Policy Dated: 12/06/22
Reference #: MC/A008	Page: 3 of 6

HAS-BLED Score Interpretation:

0 points:	1.13 bleeds per 100 patient-years
1 point:	1.02 bleeds per 100 patient-years
2 points:	1.88 bleeds per 100 patient-years
3 points:	3.74 bleeds per 100 patient-years
4 points:	8.70 bleeds per 100 patient-years
5 to 9 points:	Insufficient data (high risk)

<https://www.merckmanuals.com/medical-calculators/HASBLED.htm>

BACKGROUND:

Atrial fibrillation (AF) is one of the most common cardiac arrhythmias and a leading cause of stroke. Individuals with AF have a higher risk for stroke due to the possibility of thrombus (blood clot) formation in coronary arteries. The left atrial appendage (LAA) of the heart was previously considered to have little purpose or activity; however, due to the shape of the appendage and lack of blood flow in the area, it is believed that thrombi could develop in certain individuals. While current standard treatment for non-valvular AF focuses on anticoagulation; it is suggested that closure by exclusion or occlusion of the LAA may reduce the risk for embolic stroke from atrial thrombi. Exclusion of the LAA may be performed at the same time as another open cardiac surgical procedure.

Department of Origin: Integrated Healthcare Services	Effective Date: 12/12/23
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 12/05/23
Clinical Policy Document: Cardiac Devices & Procedures for Occlusion of Left Atrial Appendage	Replaces Effective Clinical Policy Dated: 12/06/22
Reference #: MC/A008	Page: 4 of 6

Prior Authorization: Yes, per network provider agreement.

CODING:

CPT® or HCPCS

33267 Exclusion of left atrial appendage, open, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip)

33268 Exclusion of left atrial appendage, open, performed at the time of other sternotomy or thoracotomy procedure(s), any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) (List separately in addition to code for primary procedure)

33340 Percutaneous transcatheter closure of the left atrial appendage with endocardial implant, including fluoroscopy, transeptal puncture, catheter placement(s), left angiography, left atrial appendage angiography, when performed, and radiological supervision and interpretation

C1760 Closure device, vascular (implantable/insertable)

CPT codes copyright 2023 American Medical Association. All Rights Reserved. CPT is a trademark of the AMA. The AMA assumes no liability for the data contained herein.

REFERENCES:

1. Integrated Healthcare Services Process Manual: UR015 Use of Medical Policy and Criteria
2. Clinical Policy: Coverage Determination Guidelines MP/C009
3. American College of Cardiology. 2019 AHA/ACC/HRS Focused Update of the 2014 Guideline for Management of Patients with Atrial Fibrillation. *JACC*. 2019;74(1). Retrieved from: <https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665>. Accessed 08-24-22.
4. Hijazi ZM, Saw J. Atrial fibrillation: Left atrial appendage occlusion. (Topic 928, Version 61.0; last updated: 02/24/23) In: Parikh N, ed. *UpToDate*. Waltham, MASS.: UpToDate; 2023. www.uptodate.com. Accessed 08-31-23.
5. Piayda K, Hellhammer K, Nielsen-Kudsk JE, et al. Clinical outcomes of patients undergoing percutaneous left atrial appendage occlusion in general anaesthesia or conscious sedation: data from the prospective global Amplatzer Amulet Occluder Observational Study. (2021). *BMJ Open*. 2021 Mar 24;11(3):e040455. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/33762228/>
6. Freiza X, Schmidt B, Mazzone P, et al. Comparative data on left atrial appendage occlusion efficacy and clinical outcomes by age group in the Amplatzer™ Amulet™ Occluder Observational Study. (2021). *Europace* 2021 Feb 5;23(2):238-246. Retrieved from: <https://pubmed.ncbi.nlm.nih.gov/33279979/> .
7. Ando M, Funamoto M, Cameron DE, et al. Concomitant surgical closure of left atrial appendage: a systematic review and metaanalysis. *J Thorac Cardiovasc Surg*. 2018 Sep;156(3):1071-1080.e2.
8. Atti V, Anantha-Narayanan M, Turagam MK, et al. Surgical left atrial appendage occlusion during cardiac surgery: a systematic review and meta-analysis. *World J Cardiol*. 2018 Nov 26;10(11):242-249.
9. Badhwar V, Rankin JS, Damiano RJ Jr, et al. The Society of Thoracic Surgeons 2017 clinical practice guidelines for the surgical treatment of atrial fibrillation. *Ann Thorac Surg*. 2017 Jan;103(1):329-341.
10. Basu Ray I, Khanra D, Shah S, et al. Meta-analysis comparing Watchman and Amplatzer devices for stroke prevention in atrial fibrillation. *Front Cardiovasc Med*. 2020 Jun 22; 7:89.
11. Bing S and Chen RR. Clinical efficacy and safety comparison of Watchman device versus ACP/Amulet device for percutaneous left atrial appendage closure in patients with nonvalvular atrial fibrillation: A study-level meta-analysis of clinical trials. *Clin Cardiol*. 2023 Feb;46(2):117-125.

Department of Origin: Integrated Healthcare Services	Effective Date: 12/12/23
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 12/05/23
Clinical Policy Document: Cardiac Devices & Procedures for Occlusion of Left Atrial Appendage	Replaces Effective Clinical Policy Dated: 12/06/22
Reference #: MC/A008	Page: 5 of 6

12. Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. *Eur Heart J*. 2016 Aug;37(31):2465-74.
13. Briceno DF, Villablanca P, Cyrille N, et al. Left atrial appendage occlusion device and novel oral anticoagulants versus warfarin for stroke prevention in nonvalvular atrial fibrillation: systematic review and meta-analysis of randomized controlled trials. *Circ Arrhythm Electrophysiol*. 2015 Oct;8(5):1057-64.
14. Caliskan E, Sahin A, Yilmaz M, et al. Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. *Europace*. 2018 Jul 1;20(7):e105-e114. doi: 10.1093/europace/eux211. PMID: 29016813.
15. Emmert MY, Puippe G, Baumüller S, et al. Safe, effective and durable epicardial left atrial appendage clip occlusion in patients with atrial fibrillation undergoing cardiac surgery: first long-term results from a prospective device trial. *Eur J Cardiothorac Surg*. 2014 Jan;45(1):126-31.
16. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J*. 2021 Feb 1;42(5):373-498. Erratum in: *Eur Heart J*. 2021 Feb 1;42(5):507. Erratum in: *Eur Heart J*. 2021 Feb 1;42(5):546-547. Erratum in: *Eur Heart J*. 2021 Feb 1;42(5):541-543.
17. Holmes DR Jr, Reddy VY, Gordon NT, et al. Long-term safety and efficacy in continued access left atrial appendage closure registries. *J Am Coll Cardiol*. 2019 Dec 10;74(23):2878-2889.
18. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. *J Am Coll Cardiol*. 2015 Jun 23;65(24):2614-23.
19. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. *J Am Coll Cardiol*. 2014 Jul 8;64(1):1-12. Erratum in *J Am Coll Cardiol*. 2014 Sep 16;64(11):1186.
20. Holmes DR, Reddy VY, Turi ZG, et al. PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. *Lancet*. 2009 Aug 15;374(9689):534-42.
21. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2014 Dec 2;130(23): e199-267. Erratum in: *Circulation*. 2014 Dec 2;130(23): e272-4.
22. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration with the Society of Thoracic Surgeons. *Circulation*. 2019 Jul 9;140(2): e125-e151.
23. Kar S, Doshi SK, Sadhu A, et al. PINNACLE FLX Investigators. Primary outcome evaluation of a next generation left atrial appendage closure device: results from the PINNACLE FLX trial. *Circulation*. 2021 May 4;143(18):1754-1762.
24. Labori F, Bonander C, Persson J, et al. Clinical follow-up of left atrial appendage occlusion in patients with atrial fibrillation ineligible of oral anticoagulation treatment-a systematic review and meta-analysis. *J Interv Card Electrophysiol*. 2021 Aug;61(2):215-225.
25. National Institute for Health and Care Excellence (NICE). NG196. Atrial fibrillation: diagnosis and management. April 2021.

Department of Origin: Integrated Healthcare Services	Effective Date: 12/12/23
Approved by: Medical Policy Quality Management Subcommittee	Date Approved: 12/05/23
Clinical Policy Document: Cardiac Devices & Procedures for Occlusion of Left Atrial Appendage	Replaces Effective Clinical Policy Dated: 12/06/22
Reference #: MC/A008	Page: 6 of 6

26. National Institute for Health and Care Excellence (NICE). CG180. Atrial fibrillation: the management of atrial fibrillation. June 2014. Updated August 2014.
27. Nso N, Nassar M, Zirkiyeva M, et al. Outcomes of cardiac surgery with left atrial appendage occlusion versus no occlusion, direct oral anticoagulants, and vitamin K antagonists: a systematic review with meta-analysis. *Int J Cardiol Heart Vasc.* 2022 Apr 26;40:100998.
28. Prasad RM, Saleh Y, Al-Abcha A, et al. Left atrial appendage closure during cardiac surgery for atrial fibrillation: a meta-analysis. *Cardiovasc Revasc Med.* 2022 Jul;40:26-36.
29. Reddy VY, Doshi SK, Kar S, et al. PREVAIL and PROTECT AF Investigators. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. *J Am Coll Cardiol.* 2017a Dec 19;70(24):2964-2975.
30. Reddy VY, Gibson DN, Kar S, et al. Post-approval U.S. experience with left atrial appendage closure for stroke prevention in atrial fibrillation. *J Am Coll Cardiol.* 2017b Jan 24;69(3):253-261.
31. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study with Watchman Left Atrial Appendage Closure Technology). *J Am Coll Cardiol.* 2013a Jun 25;61(25):2551-6.
32. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. *Circulation.* 2011 Feb 1;123(4):417-24.
33. Sanders GD, Lowenstern A, Borre E, et al. Stroke prevention in patients with atrial fibrillation: a systematic review update. Comparative Effectiveness Review No. 214. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290- 2015-00004-I for AHRQ and PCORI.) AHRQ Publication No. 18(19)-EHC018-EF. PCORI Publication No. 2018-SR-04. Rockville, MD: Agency for Healthcare Research and Quality; October 2018.
34. Whitlock RP, Belley-Cote EP, Paparella D, et al. LAAOS III Investigators. Left atrial appendage occlusion during cardiac surgery to prevent stroke. *N Engl J Med.* 2021 Jun 3;384(22):2081-2091.

DOCUMENT HISTORY:

Created Date: 10/12/20
Reviewed Date: 08/26/21, 08/22/22, 08/10/23
Revised Date: 01/08/21, 09/10/21, 09/26/23

Nondiscrimination & Language Access Policy

Aspirus Health Plan, Inc. complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, sexual orientation, or gender identity. *We* do not exclude people or treat them differently because of race, color, national origin, age, disability, sex, sexual orientation, or gender identity.

We will:

Provide free aids and services to people with disabilities to communicate effectively with us, such as:

- Qualified sign language interpreters
- Written information in other formats (large print, audio, accessible electronic formats, other formats)

Provide free language services to people whose primary language is not English, such as:

- Qualified interpreters
- Information written in other languages

If *you* need these services, contact *us* at the phone number shown on the inside cover of this *contract*, *your* id card, or aspirushealthplan.com.

If *you* believe that *we* have failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, sexual orientation, or gender identity, *you* can file a grievance with:

Nondiscrimination Grievance Coordinator
Aspirus Health Plan, Inc.
PO Box 1062
Minneapolis, MN 55440
Phone: 1.866.631.5404 (TTY: 711)
Fax: 763.847.4010
Email: customerservice@aspirushealthplan.com

You can file a grievance in person or by mail, fax, or email. If *you* need help filing a grievance, the Nondiscrimination Grievance Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at <http://www.hhs.gov/ocr/office/file/index.html>.

Language Assistance Services

Albanian: KUJDES: Nëse flitni shqip, për ju ka në dispozicion shërbime të asistencës gjuhësore, pa pagesë. Telefononi në 1.866.631.5404 (TTY: 711).

Arabic: تنبيه: إذا كنت تتحدث اللغة العربية، فإن خدمات المساعدة اللغوية متاحة لك مجاناً. اتصل بن اعلى رقم الهاتف 1.866.631.5404 (رقم هاتف الصم والبك : 711)

French: ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelezle 1.866.631.5404 (ATS : 711).

German: ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 1.866.631.5404 (TTY: 711).

Hindi: _यान द_ : य_द आप िहंदी बोलते ह_ तो आपके िलए मु_त म_ भाषा सहायता सेवाएं उपल_ध ह_। 1.866.631.5404 (TTY: 711) पर कॉल कर_।

Hmong: LUS CEEV: Yog tias koj hais lus Hmoob, cov kev pab txog lus, muaj kev pab dawb rau koj. Hu rau 1.866.631.5404 (TTY: 711).

Korean: 주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 1.866.631.5404 (TTY: 711)번으로 전화해 주십시오.

Polish: UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 1.866.631.5404 (TTY: 711).

Russian: ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 1.866.631.5404 (телетайп: 711).

Spanish: ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 1.866.631.5404 (TTY: 711).

Tagalog: PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nangwalang bayad. Tumawag sa 1.866.631.5404 (TTY: 711)

Traditional Chinese: 注意: 如果您使用繁體中文, 您可以免費獲得語言援助服務。請致電 1.866.631.5404 (TTY:711)。

Vietnamese: CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 1.866.631.5404 (TTY: 711).

Pennsylvania Dutch: Wann du Deitsch (Pennsylvania German / Dutch) schwetzsch, kannscht du mitaus Koschte ebbergricke, ass dihr helft mit die englisch Schprooch. Ruf selli Nummer uff: Call 1.866.631.5404 (TTY: 711).

Lao: ໄປ່ດຊາຍ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັຽຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທ 1.866.631.5404 (TTY:711).